I’m a consumer

AirTouchTM N30i

Buy Now Support

  • A tube-up nasal mask with a soft, fabric-wrapped frame and new ComfiSoftTM fabric nasal cushion. 

  • Patients rated AirTouch N30i, 10 out of 10 for feeling cooler, softer, more breathable, and less sweaty than their own masks.1

  • 97.2% of patients were confident or very confident to remain on therapy with ResMed AirTouch N30i after 90 days of use.1  

  • Available in two frame sizes with three cushion sizes and boasting a 99% fit range1 

  • Designed to work with a ResMed AirFit™ N30i and P30i cushions 


ALWAYS READ THE LABEL AND FOLLOW THE INSTRUCTIONS FOR USE. You should speak to your doctor about your symptoms and whether a CPAP device is suitable for you.

360 views
AirTouch-N30i-product
Our lightest touch yet

The exceptionally comfortable AirTouch N30i tube-up nasal mask is what you and your patients have been anticipating for. Its flexible frame is fully wrapped in super-soft, breathable fabric and features a new nasal cushion that fuses fabric with silicone for great comfort and a secure seal. 

The results are in

In an external clinical study of patients using the AirTouch N30i:

  • 99.2% of patients were confident or very confident of using the ResMed AirTouch N30i at home at initial setup.1
  • 93.5% of patients who used AirTouch N30i were able to comfortably switch sleep positions throughout the night.2
  • 92.6% of patients prefer ResMed AirTouch N30i over their own mask for long-term use with CPAP therapy.1

Wide Fit Range

In a study, ResMed AirTouch N30i had a 99% fit range based on acceptable seal and comfort during initial fitting.1,3 With three cushion sizes and two headgear options, this mask is designed to automatically adjust to different facial profiles and head shapes, providing an accurate fit the first time and saving time in your day. 

Giving patients comfort and freedom

This tube-up mask design keeps the tubing out of the way, so patients have the freedom to sleep in any position they want. A quick-release elbow on the mask also allows them to connect and disconnect from therapy with ease.  Patients can also wear glasses to read and watch TV in bed while using therapy.  

travellingwithyourequipment
Register your product

Access extra service and support by registering your ResMed product.

Learn more
resmedmyair_b2c
ResMed's myAir program

For further support, our free myAir program offers ongoing care and guidance via personalised therapy tips, coaching and advice.

Learn more
registeryourproduct
Warranty & Servicing

If you have any questions regarding warranty information on our masks, please contact our local customer service team.

Learn more

An ecosystem of solutions for individual answers

From diagnostics and healthcare informatics to therapy devices and masks, our solution can help you get a better night's rest. Crafted to offer both confidence and flexibility, our products allow for a high-quality therapy experience catered to your needs.

Our device, mask and accessory ranges, together with our online support program myAir™, enable you to easily customise your therapy experience to your preferences.

device_icon
Devices
mask_icon
Masks
accessories_icon
Accessories
mobile_icon
Connected care

References

1

ResMed conducted an external, 90-day, take-home study of the AirTouch N30i mask with 120 adults who had been on PAP therapy for OSA (≥ 6 months) and were using either the AirFit N30i or DreamWear nasal masks. The study took place at two sites in the U.S. from May 31 to November 6, 2023.

2

ResMed conducted an external, crossover (or single-arm) study of the AirTouch N30i mask, using the AirFit N30i as a benchmark, with 33 adults who had been on PAP therapy for OSA (≥ 6 months) and were using any tube-up nasal masks (AirFit N30i, DreamWear, or DreamWisp). The study took place in Sydney, Australia, from October 13 to November 11, 2021, and was conducted remotely via Zoom due to the COVID-19 pandemic.

3

Initial seal, rated 6+: 120/120=100%
Initial comfort, rated 6+: 119/120=99.2%
At start of 90-day study.

4

Combined responses of those expressing preference in an independent patient survey in the USA, UK, Germany, France & Australia, from March 2017.